Recent studies looked at biomarkers to predict diabetes, characteristics of patients who developed type 1 diabetes during adulthood, and use of oral insulin to try to prevent type 1 diabetes.
Recent industry-funded studies compared degludec, an ultralong-acting, once-daily basal insulin, to basal insulin glargine on outcomes including hypoglycemia, glucose control, and cardiovascular events.
Data from the Diabetes Prevention Program (DPP) Outcomes Study showed little effect of diabetes prevention efforts on patients' cognition or coronary artery calcium, according two recent studies.
Recent evidence suggests it may improve the prognosis of patients with cancer (see the “Keeping tabs” section in this issue).
From the ancient Egyptians to current pilot projects, two recent articles in the New England Journal of Medicine reviewed the history and current state of diabetes care.
Recent trials examined the potential effects of probiotic supplements and sucrose octasulfate dressings.
The American Heart Association and American Diabetes Association recently released a joint scientific statement on prevention of cardiovascular disease in adults with type 2 diabetes.
Studies published in the past month looked at statin prescriptions for patients with diabetes and osteoporotic fracture risk in women with diabetes.
Two recent studies analyzed the renal effects of medications for type 2 diabetes, one finding lower rates of acute kidney injury with sodium-glucose co-transporter-2 inhibitors and the other finding reduced onset of macroalbuminuria with liraglutide.
One study found that patients who developed type 2 diabetes as children had high rates of diabetes complications, while another used genetic analysis to identify patients who actually had maturity-onset diabetes of the young but had been diagnosed